{"nctId":"NCT00862251","briefTitle":"Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)","startDateStruct":{"date":"2009-04"},"conditions":["Cardiovascular Disorder","Diabetes Mellitus"],"count":808,"armGroups":[{"label":"Ezetimibe/simvastatin","type":"EXPERIMENTAL","interventionNames":["Drug: ezetimibe (+) simvastatin","Drug: atorvastatin 10 mg or simvastatin 20 mg"]},{"label":"Doubling statin dose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: simvastatin 40 mg or atorvastatin 20 mg","Drug: atorvastatin 10 mg or simvastatin 20 mg"]},{"label":"Rosuvastatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rosuvastatin","Drug: atorvastatin 10 mg or simvastatin 20 mg"]}],"interventions":[{"name":"ezetimibe (+) simvastatin","otherNames":["Vytorin"]},{"name":"simvastatin 40 mg or atorvastatin 20 mg","otherNames":["Lipitor, Zocor"]},{"name":"Rosuvastatin","otherNames":["Crestor"]},{"name":"atorvastatin 10 mg or simvastatin 20 mg","otherNames":["Lipitor, Zocor"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has not taken common statins or ezetimibe within 6 weeks of study screening or patient is currently taking a daily dose of the following statins for 6 weeks prior to study screening: simvastatin, atorvastatin, pravastatin, fluvastatin, ezetimibe, lovastatin, or ezetimibe + fluvastatin\n* Patient is willing to go on a cholesterol and glucose lowering diet for the duration of the study\n* Patient is willing to remain abstinent or use birth control for the duration of the study\n* Patient has Diabetes Mellitus with cardiovascular disease\n\nExclusion Criteria:\n\n* Patient has sensitivity to certain common statin drugs\n* Patient is Asian and would not be able to start taking the higher doses of rosuvastatin necessary for the study design\n* Patient consumes more than 2 alcoholic drinks per day\n* Patient is pregnant or breast-feeding\n* Patient has been treated with other investigational drugs within 30 days of first visit\n* Patient is currently on prohibited doses of the following statin drugs: rosuvastatin, simvastatin, atorvastatin, and pravastatin\n* Patient has congestive heart failure\n* Patient has uncontrolled high blood pressure\n* Patient has kidney disease\n* Patient has uncontrolled endocrine or metabolic disease which are known to possibly increase blood lipoproteins\n* Patient has diabetes mellitus that is not well controlled\n* Patient is human immunodeficiency virus (HIV) positive\n* Patient is currently taking medications that inhibit Cytochrome P450 3A4 (CYP3A4)\n* Patient is currently taking therapies that would increase the risk of muscle weakness\n* Patient has been taking certain over- the-counter lipid-lowering agents within 6 weeks prior to visit 1\n* Patient is currently taking psyllium or other fiber-based laxatives","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.13","spread":null},{"groupId":"OG001","value":"-8.37","spread":null}]}]}]},{"type":"SECONDARY","title":"In Participants Treated With Simvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Simvastatin","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.59","spread":null},{"groupId":"OG001","value":"-7.98","spread":null}]}]}]},{"type":"SECONDARY","title":"In Participants Treated With Atorvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Atorvastatin","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.58","spread":null},{"groupId":"OG001","value":"-8.85","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Switching Treatment to Rosuvastatin","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.13","spread":null},{"groupId":"OG001","value":"-19.32","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Reached the Target LDL-Cholesterol Level of < 70 mg/dL (1.81 mmol/L)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"171","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"134","spread":null}]}]}]},{"type":"SECONDARY","title":"In Participants Treated With Simvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of < 70 mg/dL (1.81 mmol/L)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"In Participants Treated With Atorvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of < 70 mg/dL (1.81 mmol/L)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol (TC)","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.21","spread":"17.69"},{"groupId":"OG001","value":"-4.88","spread":"15.14"},{"groupId":"OG002","value":"-10.58","spread":"15.18"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.51","spread":null},{"groupId":"OG001","value":"-2.63","spread":null},{"groupId":"OG002","value":"-3.35","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":null},{"groupId":"OG001","value":"1.00","spread":null},{"groupId":"OG002","value":"1.99","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.39","spread":null},{"groupId":"OG001","value":"-6.77","spread":null},{"groupId":"OG002","value":"-15.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL-C/HDL-C Ratio","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.55","spread":null},{"groupId":"OG001","value":"-7.39","spread":null},{"groupId":"OG002","value":"-18.99","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in TC/HDL-C Ratio","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.52","spread":null},{"groupId":"OG001","value":"-4.36","spread":null},{"groupId":"OG002","value":"-10.70","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C/HDL-C Ratio","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.77","spread":null},{"groupId":"OG001","value":"-5.32","spread":null},{"groupId":"OG002","value":"-14.64","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B (Apo B)","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.98","spread":null},{"groupId":"OG001","value":"-6.97","spread":null},{"groupId":"OG002","value":"-12.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline Apolipoprotein A-I (Apo A-I)","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","spread":null},{"groupId":"OG001","value":"-0.93","spread":null},{"groupId":"OG002","value":"0.86","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B/Apo A-I Ratio","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.67","spread":null},{"groupId":"OG001","value":"-4.75","spread":null},{"groupId":"OG002","value":"-11.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP)","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.42","spread":null},{"groupId":"OG001","value":"-1.64","spread":null},{"groupId":"OG002","value":"-9.11","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":321},"commonTop":[]}}}